Recent publication showcasing our ASC/TERT1 cells as EV production system

May 23rd, 2024, Vienna, Austria

Our telomerized human adipose derived MSC (ASC/TERT1, also known in the ATCC catalog as ASC52telo; ATCC®️ SCRC-400™️) were employed in a study recently published by ATCC and collaborators.

The study harnesses the power of a large-scale manufacturing platform to produce EVs from hTERT-immortalized mesenchymal stromal cells (ASC/TERT1). hTERT-MSC-derived EVs were tested on retinal pigment epithelial cells, both healthy and damaged, showing reparative properties similar to those from primary MSCs.

The use of hTERT-immortalized cells provides a consistent and scalable source for EV production, overcoming the variability of primary MSCs and ensuring a reliable therapeutic supply.

Browse Evercyte’s extensive portfolio of telomerized cell lines which can be grown without limitations in vitro while maintaining cell type-specific markers and functions.

Read the full article by clicking the link below.

Hindle, J.; Williams, A.; Kim, Y.; Kim, D.; Patil, K.; Khatkar, P.; Osgood, Q.; Nelson, C.; Routenberg, D.A.; Howard, M.; et al. hTERT-Immortalized Mesenchymal Stem Cell-Derived Extracellular Vesicles: Large-Scale Manufacturing, Cargo Profiling, and Functional Effects in Retinal Epithelial Cells. Cells 2024, 13, 861.